Physicians warned about counterfeit medical devices

Physicians warned about counterfeit medical devices
Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in Surgery and Medicine.

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in Surgery and Medicine.

Brian S. Biesman, M.D., from the Nashville Center for Laser and Facial Surgery in Tennessee, and Neelam Patel, from the Vanderbilt University School of Medicine in Nashville, discuss the prevalence and dangers of counterfeit medical devices, many of which target legitimate devices manufactured by Zeitiq and Ulthera.

The researchers note that both companies' devices are protected by patents and have integrated safety features. However, the counterfeit devices are not certified as safe, reliable, or reproducible, and numerous injuries have been documented with their use. There may be economic incentives for purchasing counterfeit devices, but these are outweighed by the risks and liabilities associated with using counterfeit technology. Medical malpractice insurance carriers may not provide coverage for litigation arising from use of non-U.S. Food and Drug Administration-approved devices. There are currently 29 imitations of the Zeltiq device and at least five counterfeit Ulthera devices. Despite being unregulated and unapproved, these can be purchased via the Internet and some are displayed at legitimate trade shows.

"Physicians should be aware of the existence and prevalence of counterfeit and need to understand that use of these devices in the United States can lead to severe economic, civil, and criminal penalties," the authors write.

One author disclosed financial ties to Zeltiq and Ulthera.

More information: Full Text

add to favorites email to friend print save as pdf

Related Stories

FDA warns doctors of counterfeit Botox

Dec 24, 2012

Federal regulators have warned more than 350 medical practices that Botox they may have received from a Canadian supplier is unapproved and could be counterfeit or unsafe.

Counterfeit toothpaste is discovered

Jun 14, 2007

The U.S. Food and Drug Administration said a counterfeit toothpaste falsely packaged as "Colgate" has been found in four states.

FDA: Purveyors of phony botox targeting U.S. practices

Apr 29, 2013

(HealthDay)—Medical practices that purchase Botox may unwittingly be purchasing a fraudulent product not approved by the U.S. Food and Drug Administration for sale in the United States, according to an ...

Fake Avastin contained several chemicals, no drug

Feb 28, 2012

(AP) -- Counterfeit versions of the popular cancer drug Avastin obtained by European regulators contain a variety of chemicals, but not the active ingredient found in the genuine drug, according to drugmaker Roche.

Recommended for you

US approves new, hard-to-abuse hydrocodone pill (Update)

Nov 20, 2014

U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking ...

Soaring generic drug prices draw Senate scrutiny

Nov 20, 2014

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington ...

Only half of patients take their medications as prescribed

Nov 20, 2014

The cost of patients not taking their medications as prescribed can be substantial in terms of their health. Although a large amount of research evidence has tried to address this problem, there are no well-established ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.